Geistlich acquires majority stake in O.S.T Développement
Wolhusen/Schlieren/Saint-Beauzire - Geistlich Pharma from the canton of Lucerne has acquired a majority shareholding in the French company O.S.T Développement. With this expansion, Geistlich is strengthening its allograft portfolio for dentistry and taking over the entire orthopedic business of O.S.T.
As of 1 May 2026, Geistlich Pharma, which is located in Wolhusen and part of the Geistlich Group based in Schlieren in the canton of Zurich, has acquired a majority shareholding in O.S.T Développement, headquartered in Saint-Beauzire, France. According to a statement, Geistlich aims to use the acquisition to expand its allograft portfolio for dentistry and take over the entire orthopedic business of O.S.T. Allografts are tissue transplants that are transferred from one person to another.
In 2024, Geistlich had previously secured a minority investment in the French tissue bank and medical technology company, O.S.T Développement. In the field of dentistry, O.S.T.’s allogeneic products are marketed under the brand name Allodyn. «The launch of Allodyn in France and the UK has been a real success story for us, with consistent growth from the start, excellent feedback from dentists and strong engagement from our sales team,» explained Sandrine Dupriez, Regional Manager Europe at Geistlich. The company’s distribution partners are currently in the process of launching Allodyn across their additional European markets.
At the same time, the acquisition gives Geistlich access to O.S.T’s orthopedics business, which accounts for approximately 70 percent of its sales. This will significantly expand the company’s market presence in the fields of orthopedics and sports medicine.
